The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

In everyday life, when things turn out the opposite of what you expect, it's usually a cause for frustration. In science, it's often the starting point for discovery. That's what happened to a team of ...

A randomized, clinical trial testing vutrisiran, a small-interfering RNA (siRNA) therapy for the treatment of cardiomyopathy resulting from transthyretin amyloidosis (ATTR-CM), has met its primary ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small interfering RNA (siRNA) candidates in epilepsy and Huntington’s disease. The ...